These results indicated that celecoxib inhibited inflammation during diabetes-induced muscle atrophy by inhibiting the TNF-α/NF-κB, IL-6/Stat3, and NLRP3 inflammasome pathways. The gene discussed is NFKB1; the disease is diabetes mellitus.